Advancing the World of Health
The BD Rhapsody™ single-cell platform has been a key tool for the publication of our clinical research. Food and Drug Administration and worldwide health agencies to coordinate recall activities. The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.
The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard. In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own.
BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
- The recall was initiated on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device.
- Food and Drug Administration and worldwide health agencies to coordinate recall activities.
- Backed by cutting-edge technology and more than 50 years of flow cytometry expertise
- In February 2010 BD announced a voluntary product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems.
- The lawsuit touched off a series of legal conflicts between the companies.
In certain places, BD Medical also offers consulting and analytics related services. In 2024, BD announced it would acquire Edwards Lifesciences’ critical care unit for $4.2 billion. This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation’s cannulas used in their products.
The lawsuit touched off a series of legal conflicts between the companies. The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson. We know that possibilities are endless when people feel supported and inspired. At BD, we believe that people are at the heart of every breakthrough, solution, and step forward. BD can help you optimize clinical effectiveness to help drive improvement in patient outcomes
Applications and Solutions
Quality standards, cost controls and efficiency
BD Horizon RealViolet™ 544 Reagents offer limited spillover, robust intracellular performance and lot-to-lot consistency. In December 2025, BD was sued by Tela Bio Inc., makers of a ovine forestomach matrix hernia mesh, who alleged that BD engaged in anticompetitive practices to push Tela out of the market for surgical meshes while raising prices for providers and patients. In March 2021 BD announced a recall of infusion sets for CC, GP, VP, GW/GW800, SE, and IVAC 590 Alaris Pumps and gravity infusion sets and connectors following the news that a supplier falsified sterilisation documents going back ten years. BD announced that it notified customers about the recall by letter and has been working with the U.S. The recall was initiated on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device.
It allowed us to study gene expression from immune populations of frozen PBMCs from people living with HIV after a nutritional intervention. Fill out the form to receive updates on our latest products and innovations, exclusive promotions, educational tours, and other exciting news. Backed by cutting-edge technology and more than 50 years of flow cytometry expertise Designed and validated for use with cell suspensions, whole blood and tissue pieces.
Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. Bard, Inc. and its parent company BD were fined $60 million USD for failing to adequately inform patients about health risks related to their transvaginal mesh devices. BD Medical’s Consulting services are primarily targeted at hospitals, healthcare systems and networks of healthcare providers.citation needed A comprehensive suite of trusted products, integrated solutions, useful tools and a betjili wealth of information to advance your flow cytometry applications.
